Novo Nordisk and Aspect Biosystems have entered a new phase of their collaboration aimed at developing curative cell-based medicines for diabetes. This expanded agreement builds on a partnership initiated in 2023, focusing on therapies designed to replace or repair biological functions in patients.
Technology Transfer and Operational Alignment Under the updated terms, Aspect Biosystems will acquire rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies.
-
Aspect’s Responsibility: The company will now lead the development, manufacturing, and commercialization of these cell therapies.
-
Novo Nordisk’s Involvement: The Danish firm retains rights to re-engage in late-stage development and commercialization. Additionally, certain R&D and manufacturing functions currently located in the U.S. and Denmark will be integrated into Aspect’s Canadian platform.
Investment and Financial Outlook As part of the deal, Novo Nordisk will increase its equity stake in Aspect and provide dedicated research funding. In exchange, Novo Nordisk is entitled to future milestone payments and royalties tied to product sales.
The partnership leverages Aspect’s specialized platform to develop allogeneic cellular medicines for endocrine and metabolic diseases. The primary objective remains the creation of a functional cure for Type 1 diabetes through innovative external and internal collaboration.
Source: https://www.pharmaceutical-technology.com/news/novo-nordisk-aspect-biosystems-therapies/?cf-view